GLP-1s and the Gut Microbiome
A GLP-1 medication changes three things the gut microbiome depends on at once: what a person eats, how much of it, and how quickly it moves through. It would be surprising if the community of bacteria living on that food stream did not change too, and the studies that have looked say it does. What they cannot yet say is whether the change matters — whether it contributes to the weight loss, to the side effects, or to anything a person on the drug would notice.
This page is the state of that evidence, and the practical question underneath it: when is a gut biome test worth running for someone on a GLP-1. The side effects themselves — nausea, constipation, reflux — and how they are managed belong to the GLP-1 side-effects resources and the semaglutide and tirzepatide pages.
Why the microbiome changes on a GLP-1
Three mechanisms, all of them indirect.
Diet. A person on a GLP-1 eats less, and often eats differently — less fat, less sugar, sometimes less fiber because appetite for volume falls. The gut community adapts to its food supply within days. Much of what is reported as "the GLP-1 microbiome effect" is a diet effect wearing a different label.
Motility. GLP-1s slow stomach emptying and, to a lesser degree, transit through the gut. Slower transit changes which bacteria thrive — generally favoring those that do well with more time and less oxygen — and is the same shift seen in constipation from any cause.
Weight loss itself. The obese microbiome differs from the lean one in composition and in some functional measures, and weight loss by any means — diet, surgery, medication — shifts it partway back. A GLP-1 that produces substantial weight loss will produce this shift regardless of any direct effect.
A direct effect — the drug acting on gut bacteria or on the gut wall in a way that changes the community independently of diet, motility and weight — has been proposed and is supported by some animal work, but has not been separated from the three above in people.
What the studies show
Small, mostly in people with type 2 diabetes, and mostly consistent in direction. Studies of liraglutide and semaglutide report increased abundance of some bacteria associated with a healthier metabolic profile — Akkermansia is the one most often named — and reductions in some associated with inflammation, alongside changes in short-chain fatty acid production. A 2024 systematic review pooled the human studies and found the pattern reproducible but the effect sizes modest and the designs unable to separate drug from diet. No study has shown that the microbiome change predicts who loses weight, who gets side effects, or who keeps the weight off.
There is a second line of research running the other way: whether the microbiome affects GLP-1 response. Gut bacteria produce compounds that stimulate the body's own GLP-1 secretion, and some early work suggests baseline microbiome composition correlates with how well a person responds to the drug. It is preliminary. It is also the more interesting question, and the one a test might eventually inform.
The overlap with GI side effects
The commonest reasons a person on a GLP-1 asks about their gut are constipation, bloating and a changed bowel habit — and those are side effects of the drug's action on motility, not signs of a disordered microbiome. A gut test run during the first months, while the drug is still being adjusted and the diet is still changing, will show a community in transition and will be difficult to interpret.
The practical answer to GLP-1 constipation is on the side-effects page: fiber, fluid, movement, and telling the clinician if it persists. It is not a probiotic chosen off a sequencing report. Where the microbiome genuinely enters the picture is the fiber part — appetite for bulk falls on a GLP-1, fiber intake falls with it, and the fiber-fermenting bacteria decline for want of food. That is a diet observation, and the fix is dietary.
When a gut test is worth running on therapy
Not in the first months, for the reason above. Later, in three situations. When digestive symptoms persist after the drug has been stable and the diet has settled, because at that point a persistent problem may not be the drug's. When a person wants a baseline before a substantial diet change — including the deliberate rebuilding of fiber intake that most people on a GLP-1 eventually need — so that the effect of the change can be seen. And when there is a specific reason from the main page's list: a history of gut disease, a course of antibiotics, a question the test can actually answer.
What we do not do is run the test to "optimize" a GLP-1 response, because nothing on a sequencing report currently changes how the drug is prescribed.
Frequently asked questions
Studies suggest it does — modestly, and in a direction associated with better metabolic health — but the change is hard to separate from eating less, eating differently, slower transit and weight loss itself.
No evidence for that. The change is more likely a consequence of the diet and weight change than a cause of it.
Mostly not — it is a motility effect of the drug. Reduced fiber intake on a GLP-1 does reduce fiber-fermenting bacteria, and the fix for both is dietary.
Not yet. Early research links baseline microbiome to GLP-1 response, but nothing on a current report changes prescribing.
There is no trial supporting a specific probiotic for GLP-1 users. Fiber, fluid and movement have better evidence for the digestive side effects.
After the medication is stable and the diet has settled: for persistent symptoms, as a baseline before a deliberate diet change, or for a reason on the main page's list.
Where this fits in your plan
The Gut Biome page covers when the test is worth it; the semaglutide and tirzepatide pages cover the drugs. The microbiome is a consequence of the treatment before it is a target of it.
We measure first. Then we act.
References
- Zhao L et al. Gut microbiota and GLP-1 receptor agonists: a systematic review of human studies.
- Wang Z et al. Effects of GLP-1 receptor agonists on the gut microbiota in type 2 diabetes. Frontiers in Endocrinology 2021.
- Grasset E et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metabolism 2017;25:1075–1090.
- Ley RE et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022–1023.
- Wegovy (semaglutide) prescribing information — gastrointestinal adverse reactions.
- Back toGut Biome Analysis
- Semaglutide injectionA GLP-1 receptor agonist that works with your body's appetite and blood-sugar signaling to support weight management.Read
- What a diversity score meansEvery gut test leads with a diversity number and a color. What alpha and beta diversity measure, what moves the score, why one number is not a diagnosis, and how to read a report without being sold anything.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.